Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nuvation Bio, Inc.

2.09
+0.04001.95%
Post-market: 2.100.0100+0.48%16:57 EDT
Volume:3.37M
Turnover:6.98M
Market Cap:711.15M
PE:-1.03
High:2.12
Open:2.05
Low:2.01
Close:2.05
Loading ...

Two Beaten-Down Biotech Stocks See Big Insider Buys -- Barrons.com

Dow Jones
·
29 Jun

Nuvation Bio Price Target Maintained With a $6.00/Share by JMP Securities

Dow Jones
·
25 Jun

Sector Update: Health Care Stocks Edge Higher Premarket Tuesday

MT Newswires Live
·
24 Jun

Nuvation Bio announces taletrectinib as preferred agent in NCCN Guidelines

TIPRANKS
·
24 Jun

Kerry Wentworth, Chief Regulatory Officer, Reports Acquisition of Nuvation Bio Inc. Common Shares

Reuters
·
19 Jun

JonesTrading Remains a Buy on Nuvation Bio (NUVB)

TIPRANKS
·
19 Jun

Nuvation Bio Is Maintained at Outperform by RBC Capital

Dow Jones
·
17 Jun

Nuvation Bio (NUVB) Gets a Buy from RBC Capital

TIPRANKS
·
17 Jun

RBC Cuts Price Target on Nuvation Bio to $6 From $10, Keeps Outperform, Speculative Risk

MT Newswires Live
·
17 Jun

US Pharma Bets Big on China to Snap up Potential Blockbuster Drugs

Reuters
·
17 Jun

Nuvation Bio Down Over 17%, on Track for Record Percent Decrease -- Data Talk

Dow Jones
·
13 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Cardinal Health, Adobe

Reuters
·
13 Jun

Nuvation Bio Is Maintained at Outperform by Wedbush

Dow Jones
·
12 Jun

Nuvation Bio Inc. Unveils Presentation on Global Oncology Innovations and Drug Development Progress

Reuters
·
12 Jun

Nuvation Bio down 9% after FDA approves Ibtrozi

TIPRANKS
·
12 Jun

Warnings for Nuvation’s Ibtrozi as expected, says JonesResearch

TIPRANKS
·
12 Jun

Nuvation Bio Stock Trading Halted, Pending Material News Release

MT Newswires Live
·
12 Jun

BRIEF-FDA Approves Taletrectinib For ROS1-Positive Non-Small Cell Lung Cancer

Reuters
·
12 Jun

Nuvation Bio trading halted, news pending

TIPRANKS
·
12 Jun

FDA: Approves Taletrectinib for Ros1-Positive Non-Small Cell Lung Cancer

THOMSON REUTERS
·
12 Jun